Statistics from Altmetric.com
Randomised controlled trial.
Double blind (fluoxetine and placebo), single blind (cognitive behavioral therapy (CBT) and combination treatment).
Twelve weeks (treatment period only).
US; enrolment 2000–3.
439 adolescent outpatients (aged 12–17 years) with major depressive disorder (DSM-IV).
Fluoxetine, CBT (15 sessions), fluoxetine plus CBT, or placebo for 12 weeks. 10 mg/day fluoxetine or placebo, increased up to 40 mg/day by week 8 as needed.
Physical symptoms (self-reported Physical Symptoms Checklist); mania (Adolescent Depression Scale, ADS); worsening or emergence of self-reported suicidal ideation (Suicidal Ideation Questionnaire, SIQ-Jr); clinician-rated suicidal ideation; spontaneously self-reported clinically …
For correspondence: Dr Graham Emslie, UT Southwestern Medical Centre at Dallas, 5323 Harry Hines Boulevard, Dallas, TX, USA;
Source of funding: National Institute of Mental Health.
Competing interests: Dr Dubicka has attended educational meetings sponsored by Lilly, manufacturer of fluoxetine.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.